Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.49 |
| ▸ | FABP7 | O15540 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30662743 | 1.00 | FABP5 (0.49) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL3195566 | 0.87 | FABP5 (0.47) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL3212375 | 0.86 | FABP5 (0.46) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL3203817 | 0.86 | EPHX2 (0.47) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL3209504 | 0.86 | FABP5 (0.46) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL3199959 | 0.85 | FABP5 (0.45) | FABP5FABP7KMT2AEPHX2CA1 | |
| Acetic Acid SCHEMBL6859342 | 0.85 | FABP5 (0.45) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL2946613 | 0.84 | KMT2A (0.48) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL132407 | 0.84 | FABP5 (0.47) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL3220033 | 0.84 | FABP5 (0.48) | FABP5FABP7KMT2AEPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050248-A1 | Novel amino acid and peptide inhibitors of Staphylococcus virulence | PANORAMA RESEARCH, INC. | 2003-03-13 | — | — | US | claimed |
| EP-1261362-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | Intermune, Inc. (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001058471-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | INTERMUNE, INC. (US) | 2001-08-16 | — | — | WO | claimed |
| CN-118084813-A | Macrocyclic compounds | 诺和诺德牛津研究中心有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-110691777-B | Macrocyclic compounds | 诺和诺德牛津研究中心有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-110691777-A | Macrocyclic compounds | 兹洛有限公司 | 2020-01-14 | — | — | CN | disclosed |
| US-10131658-B2 | Anti-alphavbeta1 integrin compounds and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180312500-A9 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-11-01 | — | — | US | disclosed |
| US-9682123-B2 | Methods of treating metabolic disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160376266-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | UNIV CALIFORNIA (US) | 2016-12-29 | — | — | US | disclosed |
| EP-3052515-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | The Regents of the University of California (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20020048763-A1 | Human genome-derived single exon nucleic acid probes useful for gene expression analysis | AMERSHAM PLC (GB) | 2002-04-25 | — | — | US | disclosed |
| WO-2002026818-A2 | HUMAN NEDD-1 | AEOMICA, INT. (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002024718-A1 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024750-A2 | HUMAN KIDNEY TUMOR OVEREXPRESSED MEMBRANE PROTEIN 1 | AEOMICA, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001092524-A2 | MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE | AEOMICA, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001058471-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | INTERMUNE, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| EP-0824538-A1 | SACCHAROPEPTIDES AND DERIVATIVES THEREOF | GLYCOMED INCORPORATED (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996035700-A9 | SACCHAROPEPTIDES AND DERIVATIVES THEREOF | — | 1997-02-13 | — | — | WO | disclosed |
| WO-1996035700-A1 | SACCHAROPEPTIDES AND DERIVATIVES THEREOF | GLYCOMED INCORPORATED (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312500-A9 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | ITGB1, ITGAV, ITGA1 | FABP5 2562/4885FABP7 4048/4885KMT2A 3854/4885 |
| US-10131658-B2 | Anti-alphavbeta1 integrin compounds and methods | ITGB1, ITGAV, ITGA1 | FABP5 2562/4885FABP7 4048/4885KMT2A 3854/4885 |
| US-20160376266-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | ITGB1, ITGAV, ITGA1 | FABP5 2562/4885FABP7 4048/4885KMT2A 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.